Chen Franco-Yehuda
2022
In 2022, Chen Franco-Yehuda earned a total compensation of $607.9K as Chief Financial Officer at Pluristem Therapeutics, a 55% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $44,000 |
|---|---|
| Salary | $310,253 |
| Other | $253,953 |
| Total | $607,915 |
Franco-Yehuda received $310.3K in salary, accounting for 51% of the total pay in 2022.
Franco-Yehuda also received $44K in non-equity incentive plan and $254K in other compensation.
Rankings
In 2022, Chen Franco-Yehuda's compensation ranked 4,044th out of 5,760 executives tracked by ExecPay. In other words, Franco-Yehuda earned more than 29.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,044 out of 5,760 | 30th |
Division Manufacturing | 2,283 out of 3,136 | 27th |
Major group Chemicals And Allied Products | 1,109 out of 1,422 | 22nd |
Industry group Drugs | 1,041 out of 1,323 | 21st |
Industry Biological Products, Except Diagnostic Substances | 244 out of 291 | 16th |
Source: SEC filing on February 27, 2023.
Franco-Yehuda's colleagues
We found two more compensation records of executives who worked with Chen Franco-Yehuda at Pluristem Therapeutics in 2022.
News
Pluristem Therapeutics CEO Yaky Yanay's 2023 pay jumps 111% to $2.7M
May 1, 2024
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020